For Business Use Only. Does Not Ship to Residential Addresses. For use inside an Analyzer, Sold Separately.
Thermo Kit Cocaine 100mL
Thermo Kit Cocaine 100mL
RECOMMEND SHIP UPS NEXT DAY AIR
Easily reorder reagents and American-made parts.
Enjoy the fair price promise.
Take pressure off your budget (and yourself)
Product Code: 0055
Manufacturer: Thermo Scientific
Shipping Weight: 2.00lbs (0.91kg)
Specifications
Control Sets: MGC Multi-Drug Controls
Description: DRI Cocaine Drugs of Abuse Assays
Detectable Analytes: Benzoylecgonine
DoA Calibrators: DRI Multi-Drug Calibrators
Quantity: 100mL
Storage Requirements: 2° to 8°C
Intended Use
The DRI™ Cocaine Metabolite Assay is a homogeneous enzyme immunoassay intended for the qualitative and/or semi-quantitative determination of benzoylecgonine (Cocaine Metabolite) in human urine at a cutoff concentration of either 150 ng/mL or 300 ng/mL.
The semi-quantitative mode is for the purpose of enabling laboratories to determine an appropriate dilution of the specimen for confirmation by a confirmatory method such as Liquid Chromatography/tandem mass spectrometry (LC-MS/MS) or permitting laboratories to establish quality control procedures.
Summary and Explanation of the Test
Cocaine (benzoylmethylecgonine), is derived from the plant species Erythroxylon coca, which is widely grown in South America.
Cocaine is rapidly metabolized, with less than 5% excreted unchanged in the urine. The two major metabolites, which result from enzymatic and nonenzymatic hydrolysis, are benzoylecgonine and ecgonine methyl ester. The metabolites may be detectable in urine for up to 3 weeks after long term, heavy use of cocaine.
The DRI Cocaine Metabolite Assay is a homogeneous enzyme immunoassay using ready-touse liquid reagents. The assay uses a specific antibody, which can detect benzoylecgonine in urine. The assay is based on the competition of an enzyme glucose-6-phosphate dehydrogenase (G6PDH) labeled drug and the drug from the urine sample for a fixed amount of specific antibody binding sites. In the presence of free drug from the sample, the free drug occupies the antibody binding sites, allowing the drug-labeled G6PDH to interact with the substrate, resulting in enzyme activity. In the absence of drug from the sample, the specific antibody binds to the drug labeled with G6PDH and the enzyme activity is inhibited. This phenomenon creates a direct relationship between the drug concentration in the urine and the enzyme activity. The enzyme G6PDH activity is determined spectrophotometrically at 340 nm by measuring its ability to convert nicotinamide adenine dinucleotide (NAD) to NADH.
